Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bipolar 1 Depression Clear all
Not yet recruiting Phase 4 Interventional

Neuromodulation of Mood Switch Circuitry in Bipolar Disorder

NCT07680153
View directory record Official record
Conditions
Bipolar Disorder (BD), Bipolar 1 Depression, rTMS, fMRI
Interventions
MagVenture MagPro TMS system, Sham Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 3:56 PM EDT
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 22, 2026, 3:56 PM EDT
Withdrawn Phase 2 Interventional

A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder

NCT00512616
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ceftriaxone
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 3:56 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)

NCT00939887
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
PF-04455242
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2010 · Synced Jul 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

NCT02722967
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Aripiprazole + IEM (Ingestible Event Marker)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 22, 2026, 3:56 PM EDT
Not listed Not applicable Interventional

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

NCT05705063
View directory record Official record
Conditions
Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder, Bipolar Depression, Bipolar and Related Disorders, Bipolar Disorder, Type 1, Bipolar Disorder, Type 2, Bipolar Disorder, Mixed, Obesity, Metabolic Syndrome, Ketogenic Dieting, Weight Gain, Brain Metabolic Disorder, Psychotropic Agents Causing Adverse Effects in Therapeutic Use
Interventions
LCHF Ketogenic Diet
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 22, 2026, 3:56 PM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
28
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Jul 22, 2026, 3:56 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 3:56 PM EDT
Completed No phase listed Observational

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

NCT05956483
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Costa Mesa, California • Cromwell, Connecticut • Doral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Jul 22, 2026, 3:56 PM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 22, 2026, 3:56 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

NCT05169710
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
34
States / cities
Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jul 22, 2026, 3:56 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 22, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

NCT03543410
View directory record Official record
Conditions
Depressive Episode, Bipolar 1 Depression
Interventions
SEP-4199 200 mg, SEP-4199 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 22, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

NCT00938301
View directory record Official record
Conditions
Bipolar Depression
Interventions
PF-04455242, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Jul 22, 2026, 3:56 PM EDT